LAVAL, Québec--Altasciences, a provider of early phase clinical research services, and ITR Laboratories, a nonclinical services organization, announced today their strategic alliance offering clients a way to customize their drug development programs from lead candidate selection through to early stage clinical trials. This alliance facilitates working with a single integrated partner in order to bring drug candidates to proof of concept faster, and reduce costs.
"Few organizations can offer an integrated early development solution which includes expertise in both nonclinical and clinical testing, along with personalized service. ITR and Altasciences are customer-centric full-service companies that provide the necessary focused expertise from nonclinical studies to first-in-human and proof-of-concept clinical programs, which we believe will benefit our Sponsors with customized turn-key solutions", states Chris Perkin, Chief Executive Officer at Altasciences.
"Both organizations have collaborated extensively over the past 25 years and share the same approach to customer service and flexibility – our company structure allows for quick responses and accommodates last-minute changes easily. ITR and Altasciences have already worked together to provide Bioanalytical services for complex analysis on preclinical studies that will then extend to the clinical programs, this alliance was a natural extension from which many of our clients have already benefitted", added Ginette Bain, Senior Vice President at ITR Laboratories Canada.
The alliance provides our clients with a single coordinated team throughout the drug development process, minimizing delays and time lost during the transition from nonclinical to clinical development. In addition, the partnership will provide our clients with guidance that leverages both ITR's and Altasciences' experience, knowledge, location and close working relationship throughout the process.
Altasciences, owned by Kilmer Capital Partners, owns Algorithme Pharma, Algorithme Pharma USA and Vince and Associates Clinical Research. All organizations operate with a common mission, to provide the best quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service.
ITR Canada Inc., owned by Biology and Zoology Research Center of Japan, is an international Contract Research Organization that provides non-clinical toxicology services for the biotechnology and pharmaceutical industries globally. ITR offers personalized services from planning and study program design to study implementation and reporting for regulatory drug filing. ITR Canada is CCAC and AAALAC accredited, and studies conducted are fully compliant with GLP.